Bruton agammaglobulinemia tyrosine kinase
Bruton agammaglobulinemia tyrosine kinase
Overview
Bruton agammaglobulinemia tyrosine kinase (BTK) is a non-receptor tyrosine kinase that plays an essential and non-redundant role in B-cell development, maturation, and signaling. It is a member of the Tec family of kinases and is encoded by the BTK gene located on the X chromosome. BTK was originally identified as the gene mutated in X-linked agammaglobulinemia (XLA), a primary immunodeficiency characterized by the near-complete absence of circulating B cells and immunoglobulins. In physiological B-cell biology, BTK functions as a pivotal component of the B-cell receptor (BCR) signaling cascade, transmitting activation signals downstream through phospholipase C gamma 2 (PLCG2) and connecting to pathways including the PI3K/Akt signaling pathway, NF-κB, and MAPK. Beyond its canonical role in lymphocytes, BTK is expressed in myeloid lineage cells including neutrophils and macrophages, where it participates in innate immune receptor signaling.
Given its central position in BCR-mediated survival and proliferation signals, BTK has emerged as one of the most validated pharmacological targets in hematological oncology. Small-molecule inhibitors of BTK — spanning covalent, irreversible agents (such as ibrutinib) and next-generation non-covalent inhibitors — have transformed the treatment landscape for B-cell malignancies, particularly chronic lymphocytic leukemia (CLL). More recently, BTK has attracted attention in inflammatory and autoimmune disorders, as well as in exploratory investigations in neurological conditions, reflecting the breadth of its signaling roles across hematopoietic and immune cell types.
Focus of Latest Publications
Recent publications demonstrate that Bruton tyrosine kinase (BTK) remains a central therapeutic target across multiple disease contexts. BTK functions as a key signaling molecule in B cells, myeloid cells, and platelets, with distinct roles in cell activation, antibody production, and inflammatory pathways. The breadth of current research reflects both the maturation of BTK-targeting therapies and the ongoing challenge of overcoming acquired resistance in treated populations.
In hematologic malignancies—particularly chronic lymphocytic leukemia, small lymphocytic lymphoma, and diffuse large B-cell lymphoma—BTK inhibitors and a new class of BTK degraders are under active investigation. Phase 2 and Phase 1 trials demonstrate activity of next-generation non-covalent inhibitors such as docirbrutinib and rocbrutinib in heavily pretreated populations with prior BTK exposure, alongside rapid and deep responses from BTK degraders including bexobrutideg and BGB-16673. In primary central nervous system lymphoma, the highly selective BTK inhibitor orelabrutinib crosses the blood-brain barrier effectively and shows superior outcomes when combined with methotrexate in patients with MyD88L265P mutations, providing a molecular rationale for frontline incorporation of BTK-directed therapy in this aggressive setting. Combination approaches with lenalidomide demonstrate acceptable tolerability and antitumor activity in relapsed/refractory diffuse large B-cell lymphoma, with overall response rates approaching 58% at optimal dosing.
Beyond hematologic malignancies, BTK targeting addresses diverse pathologic roles. BTK degradation by NX-5948 provides selective antithrombotic benefits by impairing platelet activation through the GPVI pathway while preserving thrombin-mediated hemostasis, establishing a therapeutic window distinct from existing antiplatelet agents. In neuroinflammatory contexts, zinc supplementation inhibits BTK phosphorylation in macrophages to mitigate Japanese encephalitis virus-induced brain inflammation, and BTK has been identified as a common biomarker of both Alzheimer's disease and postoperative delirium, suggesting a shared immunopathologic axis. BTK activity in neutrophils is essential for initiating and maintaining skin inflammation in pemphigoid diseases, and selective BTK inhibition shows efficacy in rheumatoid arthritis through suppression of B-cell activation and autoantibody production.
The emergence of BTK resistance mechanisms shapes current drug development priorities. Four prevalent catalytic domain mutations—A428D, T474I, C481S, and L528W—significantly reduce binding free energies of non-covalent inhibitors and disrupt critical inhibitor-protein interactions, explaining clinical relapse in chronic lymphocytic leukemia. BTK degraders introduce a mechanistically distinct modality that may overcome certain covalent inhibitor resistance patterns, though downstream signaling escape and disease-dependent adaptive programs continue to present evolving challenges. Ongoing optimization of BTK-directed agents encompasses both structure-guided discovery of novel chemotypes and pharmacokinetic modeling to establish appropriate dosing across patient populations, reflecting sustained commitment to expanding BTK-targeting efficacy beyond current clinical limitations.